María Díez Campelo-rekin lankidetzan egindako argitalpenak (27)

2023

  1. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

  2. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2019

  1. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

    British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

  2. SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: An alternative approach against acute myeloid leukemia

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  3. The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability

    Stem Cells, Vol. 37, Núm. 10, pp. 1357-1368

2018

  1. Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 3, pp. 443-451

2016

  1. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

    Leukemia Research, Vol. 39, Núm. 3, pp. 296-306

2014

  1. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

  2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

  3. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585

2013

  1. Uptake and delivery of antigens by mesenchymal stromal cells

    Cytotherapy, Vol. 15, Núm. 6, pp. 673-678

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

  2. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

    Haematologica, Vol. 97, Núm. 8, pp. 1218-1224

  3. Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use

    Transfusion Medicine, Vol. 22, Núm. 2, pp. 122-127

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

  2. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population

    Haematologica, Vol. 94, Núm. 7, pp. 975-983

2008

  1. Beclometasone dipropionate: A topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease

    Expert Opinion on Investigational Drugs, Vol. 17, Núm. 9, pp. 1389-1401